NasdaqTicker change · was TCGX
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 5d agoAfter-hours26.10.20 06:12425Other#●●●#●●●
TCGX Acquisition Corp.
TCGX Acquisition Corp. is pursuing a business combination with TriGemX Bio and intends to file a registration statement on Form S-4 with the SEC. The proposed combination is subject to approval by TCGX shareholders, and proxy materials will be distributed to shareholders once the registration statement becomes effective.…more
Detected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 06:11425Other
TCGX Acquisition Corp.
TCGX Acquisition Corp. is pursuing a business combination with TriGemX Bio valued at approximately $600 million, with completion expected in the first quarter of 2027. Upon closing, TriGemX will have $246 million in cash to support the Phase 3 clinical trial and potential commercialization of its migraine drug, elismetrep.…more
View filingShare - 6d agoPre-market26.10.19 22:25425Other
TCGX Acquisition Corp.
TCGX Acquisition Corp. has entered into a definitive business combination agreement with TriGemX Bio, Inc., with the merger expected to close in the first quarter of 2027. TriGemX is valued at an agreed pre-money equity value of $361 million. Additionally, TCGX secured $160 million in gross proceeds through a PIPE financing round at $10.00 per share.…more
View filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:07#●●●#●●●#●●●
TriGemX Bio to Go Public via SPAC Merger with TCGX Acquisition
Biotech firm TriGemX Bio will go public on Nasdaq through a merger with SPAC TCGX Acquisition. The transaction is expected to provide the combined company with approximately $246 million in gross proceeds.…more
Detected5m · 30m · 60m · Next dayPLUSShareBenzinga